DelveInsight Business Research LLP

DelveInsight’s report titled “Sarcopenia – Market Insights, Epidemiology, and Market Forecast – 2032” comprehensively analyzes the Sarcopenia market, including market insights, market forecasts, drug uptakes, and drug penetration.

The report examines historical epidemiology data for Diagnosed Prevalent Cases and projects the same for the forecast period. Sarcopenia-diagnosed cases are further segmented by gender. The report also offers an in-depth understanding of various aspects of the disease, including diagnosis algorithm, prescription patterns, physician perceptions on treatment, and current and future market developments for the 7MM, including the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan from 2019 to 2032.

Sarcopenia Key Highlights 

• The Key companies working in Nevoid Basal Cell Carcinoma are Biophytis, MyMD Pharmaceuticals, Turn Biotechnologies, Oncocross, NMD Pharma, and many others
• The Key Therapies for Nevoid Basal Cell Carcinoma include(BIO101), RJx-01, and many others 
• The Market Size for Nevoid Basal Cell Carcinoma market is expected to be USD XX Million by 2032.
• The CAGR for Nevoid Basal Cell Carcinoma market is expected to be XX%.

Sarcopenia Overview

Sarcopenia is a musculoskeletal disease in which muscle mass, strength, and performance are significantly compromised with age. Sarcopenia most commonly affects elderly and sedentary populations and patients who have comorbidities that affect the musculoskeletal system or impair physical activity. Such musculoskeletal degeneration may impede daily activities and demonstrates predictive value regarding unfavorable postoperative outcomes, and increased complication rates, mortality, and morbidity in major surgical procedures. Additionally, sarcopenia is strongly associated with a greater incidence of falls and increased fracture risk. Furthermore, decreased muscle mass or muscle function, both criteria for sarcopenia, are risk factors for loss of independence in patients over the age of 90 years old.

Generally, a significant decline of type II, but not type I muscle fibers are observed in sarcopenic patients. Several mechanisms of the underlying pathophysiology of sarcopenia have been described: i) Age-related declines in anabolic hormone serum concentrations: Normal physiological serum levels of anabolic hormones such as testosterone, human growth hormone (HGH), and insulin-like growth factor-1 (IGF-1) have been demonstrated to function in the development, maintenance, or rejuvenation of muscle tissue. Age-related declines of such hormones are observed in patients with sarcopenia and thus, support this underlying pathophysiology of the disease. ii) Acne Vulgaris with “sarcopenic obesity”: Aging patients often experience changes in body composition represented by increased adipose tissue alongside decreased muscle mass, coined as “sarcopenic obesity.” These changes are associated with metabolic dysfunction, including Acne Vulgaris (IR), leading to the accumulation of visceral fat mass. Iii) Age-related neurodegeneration

Sarcopenia Epidemiology Insights

• Sarcopenia was estimated to influence 10 % to -16 % of the elderly worldwide. The prevalence of sarcopenia was higher among patients compared to general populations. The prevalence of sarcopenia ranged from 18 % in diabetic patients to 66 % in patients with unresectable esophageal cancer.

Click here to learn more about the Sarcopenia Market Landscape

The Report Covers the Sarcopenia  Epidemiology Segmented by:

• Total Sarcopenia prevalent cases  

• Total Sarcopenia incident cases 

• Total Sarcopenia treated cases 

• Total Sarcopenia diagnosed cases 

Sarcopenia Market Outlook 

The Sarcopenia market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Acne Vulgaris market trends by analyzing the impact of current Acne Vulgaris therapies on the market, unmet needs, drivers barriers, and demand for better technology. This segment gives a thorough detail of the Acne Vulgaris market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Acne Vulgaris market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Acne Vulgaris market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Companies Working in the Sarcopenia Market

• Biophytis

• MyMD Pharmaceuticals

• Turn Biotechnologies

• Oncocross

• NMD Pharma

And many others 

Sarcopenia Therapies Covered and Analyzed in the Report

• BIO101

• MYMD-1

And many others 

Learn more about the Key Companies and Emerging Therapies in the Sarcopenia  Market

Table of Contents 

1.  Key Insights 

2.  Sarcopenia  Introduction 

3.  Executive Summary of  Sarcopenia        

4.  Disease Background and Overview

5.  Epidemiology and patient population

6.  Sarcopenia  Emerging Therapies

7.  Sarcopenia  Market Outlook

8.  Market Access and Reimbursement of Therapies

9.  Market Drivers 

10.  Market Barriers 

11.  Appendix

12.  Report Methodology

13.  DelveInsight Capabilities

14.  Disclaimer

Learn about the detailed offerings of the report @ Sarcopenia  Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services